MOLN Stock Overview
A clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Molecular Partners AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CHF 4.55 |
52 Week High | CHF 9.50 |
52 Week Low | CHF 3.04 |
Beta | 0.61 |
11 Month Change | -17.42% |
3 Month Change | -16.51% |
1 Year Change | 1.11% |
33 Year Change | -75.14% |
5 Year Change | -70.30% |
Change since IPO | -79.69% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Molecular Partners' (VTX:MOLN) Cash Burn Rate
Sep 10We Think Some Shareholders May Hesitate To Increase Molecular Partners AG's (VTX:MOLN) CEO Compensation
Apr 11Is Molecular Partners (VTX:MOLN) In A Good Position To Invest In Growth?
Jan 09Here's Why We're Watching Molecular Partners' (VTX:MOLN) Cash Burn Situation
Sep 08Need To Know: The Consensus Just Cut Its Molecular Partners AG (VTX:MOLN) Estimates For 2023
Jun 23What You Need To Know About The Molecular Partners AG (VTX:MOLN) Analyst Downgrade Today
Aug 31Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth Plans
May 09Upgrade: Analysts Just Made A Substantial Increase To Their Molecular Partners AG (VTX:MOLN) Forecasts
Dec 26We're Hopeful That Molecular Partners (VTX:MOLN) Will Use Its Cash Wisely
Jun 24Molecular Partners AG (VTX:MOLN) Could Be Less Than A Year Away From Profitability
Mar 09Analysts Just Made A Major Revision To Their Molecular Partners AG (VTX:MOLN) Revenue Forecasts
Feb 10Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth Plans
Jan 21How Much Of Molecular Partners AG (VTX:MOLN) Do Insiders Own?
Dec 17Downgrade: Here's How Analysts See Molecular Partners AG (VTX:MOLN) Performing In The Near Term
Nov 21Shareholder Returns
MOLN | CH Biotechs | CH Market | |
---|---|---|---|
7D | -10.6% | 1.0% | -3.4% |
1Y | 1.1% | 54.8% | 5.8% |
Return vs Industry: MOLN underperformed the Swiss Biotechs industry which returned 54.8% over the past year.
Return vs Market: MOLN underperformed the Swiss Market which returned 5.8% over the past year.
Price Volatility
MOLN volatility | |
---|---|
MOLN Average Weekly Movement | 14.0% |
Biotechs Industry Average Movement | 9.4% |
Market Average Movement | 3.5% |
10% most volatile stocks in CH Market | 7.2% |
10% least volatile stocks in CH Market | 1.6% |
Stable Share Price: MOLN's share price has been volatile over the past 3 months.
Volatility Over Time: MOLN's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2004 | 162 | Patrick Amstutz | www.molecularpartners.com |
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors.
Molecular Partners AG Fundamentals Summary
MOLN fundamental statistics | |
---|---|
Market cap | CHF 151.03m |
Earnings (TTM) | -CHF 57.63m |
Revenue (TTM) | CHF 7.86m |
19.2x
P/S Ratio-2.6x
P/E RatioIs MOLN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MOLN income statement (TTM) | |
---|---|
Revenue | CHF 7.86m |
Cost of Revenue | CHF 50.71m |
Gross Profit | -CHF 42.85m |
Other Expenses | CHF 14.78m |
Earnings | -CHF 57.63m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.74 |
Gross Margin | -544.98% |
Net Profit Margin | -732.97% |
Debt/Equity Ratio | 0% |
How did MOLN perform over the long term?
See historical performance and comparison